Becton, Dickinson and (NYSE:BDX – Get Rating) and Accuray (NASDAQ:ARAY – Get Rating) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership and profitability.
Institutional & Insider Ownership
87.1% of Becton, Dickinson and shares are owned by institutional investors. Comparatively, 63.4% of Accuray shares are owned by institutional investors. 0.3% of Becton, Dickinson and shares are owned by insiders. Comparatively, 2.9% of Accuray shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a summary of recent ratings for Becton, Dickinson and and Accuray, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Becton, Dickinson and||0||1||7||0||2.88|
Volatility and Risk
Becton, Dickinson and has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.
Earnings & Valuation
This table compares Becton, Dickinson and and Accuray’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Becton, Dickinson and||$18.87 billion||3.64||$1.78 billion||$5.33||45.36|
|Accuray||$429.91 million||0.80||-$5.35 million||($0.11)||-32.55|
Becton, Dickinson and has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.
This table compares Becton, Dickinson and and Accuray’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Becton, Dickinson and||8.59%||12.98%||6.19%|
Becton, Dickinson and beats Accuray on 10 of the 14 factors compared between the two stocks.
About Becton, Dickinson and
Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.
Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes CyberKnife and Tomo Therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The company was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.